Skip to main content
Fig. 5 | Infectious Diseases of Poverty

Fig. 5

From: Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries

Fig. 5

Patient HIV-1 RNA Load and CD4+ T Cell Count Receiving First Line Treatment Pre/Post Sanger Resistance Testing. a Patients (n = 157) at the time of Sanger DR testing with resistance to AZT. b AZT susceptible patients (n = 99) at the the time of Sanger DR testing. c Patients (n = 39) resistant to AZT by AfriPOLA. Means and statistically significant differences (ANOVA) are indicated

Back to article page